A Phase 1 interventional study of 4P-004 and Placebo in Knee Osteoarthritis, sponsored by 4Moving Biotech. Completed at 3 sites in Belgium. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by 4Moving Biotech · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.
Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 30th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 39th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Next Biomedical Co., Ltd. · Sites in Belgium, Netherlands
Ages 50+
Medisch Centrum Latem · Sites in Belgium
Ages 18–85
Ziekenhuis Oost-Limburg · Sites in Belgium, Netherlands
Ages 18+
Sint-Trudo Hospital · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 86 across the 38 interventional studies, 190 across the 8 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 46 have an industry lead sponsor. The 10 most frequent:
4Moving Biotech is the lead sponsor of 2 studies on the registry; none are open to participants now.
4Moving Biotech has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteoarthritis, Knee with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387473Vrije Universiteit BrusselAdded Value of Cognitive Behavioural Therapy for Insomnia in Persons With Knee Osteoarthritis | 2026-12 |
| NCT07465601Medisch Centrum LatemDaily Activity and Clinical Outcome Measurement of Arthrosamid® Administration in Symptomatic Knee Osteoarthritis. | 2027-01-31 |
| NCT06930677Next Biomedical Co., Ltd.Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200 | 2027-02 |
| NCT06891807Medisch Centrum LatemComparison of Image Based Robotic Total Knee Arthroplasty vs Imageless Augmented Reality Assisted Total Knee Arthroplasty | 2027-10-01 |
| NCT02766231Limacorporate S.p.aPhysica CR and Physica PS Clinical Trial | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase I study is a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and tolerability of single ascending dose of IA 4P-004 in participants,
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4P-004 is administered once intraarticularly in the target knee joint Dose = w mg
Drug: 4P-004
4P-004 is administered once intraarticularly in the target knee joint Dose = x mg
Drug: 4P-004
4P-004 is administered once intraarticularly in the target knee joint Dose = y mg
Drug: 4P-004
4P-004 is administered once intraarticularly in the target knee joint Dose = z mg
Drug: 4P-004
Placebo is administered once intraarticularly in the target knee joint
Drug: Placebo
single intraarticular administration in the knee joint
Also known as: Liraglutide
single intraarticular administration in the knee joint
Also known as: NaCl
Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA.
Number of participants with Adverse Events, serious AEs (SAEs), with abnormal Vital signs, abnormal ECG reading and abnormal Laboratory test results
Time frame: Day 1-Day 28
To Characterize the Plasma Concentration of Liraglutide When Administered as Single IA Doses at Escalating Dose Levels in Participants With Knee OA
Plasma concentration of liraglutide following a single IA injection at pre-injection (Time \[-4hours-0\]) and 2hours, 4hours, 8hours, 12hours, 16hours and 24-hours post injection.
Time frame: Day 1 to Day 2
Exploratory Biomarkers Identification
Serum and urine OA-related biomarkers (exploratory proteomic research of 4P-004 efficacy-related biomarkers) at Day 1 (Time \[-4-0\]hours, Time 8hours), Day 2 (Time 24hours) and Day 8.
Time frame: Day 1, Day 2, Day 8
| Milestone | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 | 2 |
| Completed | 6 | 0 | 0 | 0 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| Started | 0 | 6 | 0 | 0 | 2 |
| Completed | 0 | 6 | 0 | 0 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 6 | 0 | 2 |
| Completed | 0 | 0 | 6 | 0 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 | 2 |
| Completed | 0 | 0 | 0 | 8 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Number of participants with Adverse Events, serious AEs (SAEs), with abnormal Vital signs, abnormal ECG reading and abnormal Laboratory test results
| participants | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| TEAE | 5 | 5 | 5 | 6 | 6 |
| SAE | 0 | 0 | 1 | 0 | 0 |
| Abnormal Vital Sign | 0 | 0 | 0 | 0 | 0 |
| Abnormal Laboratory Value | 0 | 0 | 0 | 0 | 0 |
| Abnormal ECG | 0 | 0 | 0 | 0 | 0 |
Plasma concentration of liraglutide following a single IA injection at pre-injection (Time \[-4hours-0\]) and 2hours, 4hours, 8hours, 12hours, 16hours and 24-hours post injection.
| ng/mL | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| Time [-4hours-0] | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | — |
| Time 2 hours | 3.6 ± 1.1 | 7.2 ± 4.2 | 58.1 ± 38.8 | 24.6 ± 15.7 | — |
| Time 4 hours | 5.3 ± 1.8 | 13.9 ± 7.5 | 90.4 ± 58.6 | 41.6 ± 18.4 | — |
| Time 8 hours | 7.3 ± 3.1 | 23.2 ± 12.4 | 123.7 ± 74.9 | 64.5 ± 23.0 | — |
| Time 12 hours | 7.1 ± 3.1 | 24.5 ± 12.9 | 122.2 ± 69.2 | 67.2 ± 24.7 | — |
| Time 16 hours | 6.4 ± 2.9 | 23.5 ± 12.0 | 113.6 ± 61.8 | 63.8 ± 25.4 | — |
| Time 24 hours | 5.0 ± 2.4 | 20.0 ± 9.4 | 95.2 ± 52.1 | 53.6 ± 25.4 | — |
Serum and urine OA-related biomarkers (exploratory proteomic research of 4P-004 efficacy-related biomarkers) at Day 1 (Time \[-4-0\]hours, Time 8hours), Day 2 (Time 24hours) and Day 8.
Results for this outcome have not been posted.
Collected over For each participant, adverse events were collected from screening until the End of study (D29). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 4P-004 w mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| 4P-004 x mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| 4P-004 y mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| 4P-004 z mg | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Placebo | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Event | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/8 | 0/8 |
| Event | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/6 | 1/6 | 5/6 | 2/8 | 2/8 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 5/6 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 3/6 | 1/6 | 2/6 | 4/8 | 1/8 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 2/6 | 1/8 | 1/8 |
| Injection site painGeneral disorders | 0/6 | 2/6 | 0/6 | 0/8 | 0/8 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/6 | 1/6 | 0/6 | 1/8 | 0/8 |
| Abdominal distensionGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 2/8 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/6 | 1/6 | 1/6 | 2/8 | 2/8 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/8 | 0/8 |
| Gastric dilatationGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/8 | 0/8 |
| Age, Continuous(years) | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 62.5 ± 6.9 | 54.2 ± 5.3 | 60.3 ± 8.5 | 59.1 ± 59.5 | 63.5 ± 11.5 | 60.1 ± 9.1 |
| Sex: Female, Male(Participants) | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 4 | 5 | 5 | 19 |
| Male | 3 | 4 | 2 | 3 | 3 | 15 |
| Race and Ethnicity Not Collected(Participants) | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | 0 |
| BMI(kg/m2) | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 29 ± 6.8 | 28 ± 5.1 | 28.5 ± 4.9 | 25.5 ± 5 | 29.5 ± 4.3 | 28.1 ± 5.1 |
| Kellgren-Lawrence score(Participants) | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Kellgren-Lawrence 2 | 2 | 4 | 3 | 6 | 6 | 21 |
| Kellgren-Lawrence 3 | 4 | 1 | 3 | 1 | 2 | 11 |
| Kellgren-Lawrence 4 | 0 | 1 | 0 | 1 | 0 | 2 |
| NRS(units on a scale) | 4P-004 w mg | 4P-004 x mg | 4P-004 y mg | 4P-004 z mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 3.8 ± 2.3 | 4.0 ± 2.0 | 3.5 ± 2.6 | 3.5 ± 2.3 | 3.7 ± 2.4 | 3.7 ± 2.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Oct 2023, 14 months.
Results were first posted in May 2025, 1 year 6 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 14 months is close to that.
Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide
4Moving Biotech